Catalog No. | HY377026 |
---|---|
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Host species | Humanized |
Isotype | IgG1 |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter, 36 kDa nucleolar protein HNP36, ENT2, Equilibrative nucleoside transporter 2, SLC29A2, Hydrophobic nucleolar protein, 36 kDa, Equilibrative NBMPR-insensitive nucleoside transporter, Nucleoside transporter, ei-type, Delayed-early response protein 12, Solute carrier family 29 member 2, HNP36, DER12 |
Concentration | 1mg/ml |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G, purified from cell culture supernatant. |
Accession | Q14542 |
Form | Liquid |
Storage buffer | 0.01M PBS,pH7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -433°C. |
Alternate Names | VAL-1221,CAS:2145123-44-8 |
Background | Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research. |
Note | For research use only. Not for use in clinical or therapeutic applications. |
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France